GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GlaxoSmithKline has announced ... the minority buy-out of the consumer healthcare business and a series of non-core product divestments.” ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and ... it rejected a £50 billion approach from Unilever for its consumer health joint venture with Pfizer, which according to ...

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...

GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone needs almost every day. These stocks are able to sustain any economic ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...